Therefore, new strategies have been proposed for the development of more safe anti-obesity agents, such as the identification of peripherally restricted CB1 receptor antagonists [71] as well as neutral CB1 receptor antagonists or CB1 allosteric modulators [72]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.